Avil 22.7Tablet

Generic

Pheniramine Maleate.

Indications

Pheniramine Maleate is indicated for-

• Allergic conditions including hay fever, drug rashes, angioneurotic edema, serum sickness, allergic conjunctivitis, food allergy etc.
• Conditions of the respiratory tract that are accompanied by increased secretion, including vasomotor rhinitis and acute rhinitis.
• All itching skin conditions, including neurodermatitis, eczema of any origin, lichen planus, acute and chronic urticaria, pruritis of the anus or genitals, pruritus in icterus and diabetes, radiation sickness etc.
• Prevention and treatment of motion sickness.
• Prevention and treatment of nausea, vomiting and vertigo due to Meniere’s disease and other labyrinthine disturbances.

Pharmacology

Pheniramine competes with histamine for the histamine H1 receptor, acting as an reverse agonist once bound. The diminishment in H1 receptor movement is dependable for decreased tingling as well as decreased vasodilation and capillary spillage driving to less redness and edema. This could be seen within the concealment of the histamine-induced wheal (swelling) and flare (vasodilation) response. Inverse agonism of the H1 receptor within the CNS is additionally mindful for the sedation delivered by first-generation antihistamines like pheniramine. The authoritative of pheniramine to H4 receptors, and ensuing reverse agonism, may moreover contribute to diminished tingling by antagonizing aggravation.

Dosage & Administration

Doses must be individually determined in all cases and should be taken with or soon after food. Treatment should be commenced at the lowest possible dose because experience has shown that antihistamines are often effective at low doses. The maximum dose of 3 mg/kg per day should not be exceeded. Elderly patients should use the adult dose with caution.

To prevent travel sickness, it is recommended that the first dose be taken at least 30 minutes before traveling. Due to the risk of drowsiness, the patient should not drive a motor vehicle or operate machinery after taking a dose.

Pheniramine Maleate tablets:

• In adults and children over 10 years of age: Treatment is commenced with half a tablet taken up to three times daily. This dose may be increased to one tablet taken up to three times daily if required.
• Children 5-10 years of age: Half a tablet up to three times daily. Pheniramine Maleate tablets are not recommended in children under 5 years of age.

Interaction

MAO-inhibitors may draw out and escalating the anticholinergic impact of pheniramine. Adverse CNS impacts of pheniramine may be improved when it is taken with liquor or other CNS depressants. Atropine and related drugs may improve the anticholinergic movement of pheniramine.

Contraindications

Patients with touchiness to pheniramine or any other fixing. Patients with symptomatic prostatic hypertrophy. Patients accepting MAO-inhibitor therapy. Newborn and untimely newborn children.

Side Effects

The most common adverse reaction is sedation, which often disappears after a few days if tolerance is acquired. Hypersensitivity reactions have been reported.

• Central Nervous System: Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Agitation and convulsions, especially in children and restlessness, disorientation and hallucinations in adults, are common symptoms following overdose.
• Gastrointestinal: Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation.
• Genitourinary: Urinary retention.
• Cardiovascular: Palpitations, headache.
• Ocular: Blurred vision, increased intraocular pressure.
• Musculoskeletal: Muscular weakness.
• Haematological: Rare cases of blood dyscrasias including agranulocytosis and haemolytic anaemia have been reported.

Pregnancy & Lactation

pregnancy Category A. Utilize as it were in case entirely shown. Utilize as it were in case entirely demonstrated.

Precautions & Warnings

• Pheniramine Maleate may cause drowsiness. Both the dosage and the time of administration should be carefully considered in patients whose activities (e.g. driving a car or operating machinery) demand special concentration.
• Patients should be cautioned against the simultaneous ingestion of alcohol and other central nervous system depressants. Pheniramine Maleate may possibly be hallucinogenic in toxic doses. Due to the possible CNS stimulating effects of antihistamines, pheniramine has the potential for abuse.
• Due to the anticholinergic effect of pheniramine, caution and close monitoring are required if it is used in patients with conditions such as prostatic hypertrophy, narrow angle glaucoma, asthma or severe cardiovascular disease.
• The anti-emetic effect of pheniramine may mask the signs of other conditions. Products containing pheniramine should not be taken on an empty stomach.

Therapeutic Class

Anti-histamine sedative.

Storage Conditions

Do not store at temperatures above 30°C. Keep out of the reach of youngsters and away from light.

Pharmaceuticals name

Sanofi Bangladesh Ltd.